Implantable cardioverter-defibrillator implantation
Implantable cardioverter-defibrillator implantation has been studied in 2 papers since 2026: 2 observational studies in people; 2 in the past year. The newest paper, Nov 2, 2026: “Age-Stratified Outcomes Following Non-ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock: A Propensity-Matched Analysis”.
2 papers study it1 findingUpdated
2 new papers in 30 daysSee all 2 papers on implantable cardioverter-defibrillator implantation
At a glance
The findings reach people, from one lab or study. 1 lab.
“Despite lower mortality, patients aged 65-74 years experienced greater long-term cardiovascular morbidity, including ventricular arrhythmias, heart failure hospitalization, and implantable cardioverter-defibrillator implantation.”
- 1 lab
- Humans2
What is implantable cardioverter-defibrillator implantation linked with?
1Studies link implantable cardioverter-defibrillator implantation with 1 measure, most often age 65–74 years (1 study).
Age 65–74 years
upin humans1HR 2.38
1 study
Age 65–74 years
upin humans1HR 2.38
Age 65–74 years are associated with implantable cardioverter-defibrillator implantation in humans (NSTEMI complicated by cardiogenic shock; propensity score-matched comparison) (0.80% vs 0.27%; HR 2.38, 95% CI 1.54–3.67).
“Despite lower mortality, patients aged 65-74 years experienced greater long-term cardiovascular morbidity, including ventricular arrhythmias, heart failure hospitalization, and implantable cardioverter-defibrillator implantation.”
HumansNSTEMI complicated by cardiogenic shock; propensity score-matched comparison180 days
AHA Scientific Sessions 2026 abstract